Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival

Purpose: From the published literature, we identified 23 germ line sequence variants in 17 genes from hypothesis-generating studies that were associated with prognosis of head and neck cancer, including sequence variants of DNA repair (ERCC1, ERCC4, ERCC5, MSH2, XPA, ERCC2, XRCC1, XRCC3), DNA methylation (DNMT3B), cell cycle and proliferation (CCND1, TP53), xenobiotic metabolism (GSTM1, GSTT1, CYP2D6), metastatic -potential (MMP3), immunologic (CTLA4), and growth factor pathways (FGFR4). The purpose of this study was to validate the role of these 23 sequence variants for overall (OS) and disease-free survival (DFS) in a large, comprehensive, well-annotated data set of patients with head and neck cancer. Experimental Design: We genotyped these sequence variants in 531 patients with stage I and II radiation-treated head and neck cancer (originally recruited for an alpha-tocopherol/beta-carotene placebo-controlled secondary prevention study), and analyzed using Cox proportional hazards models, stratified by treatment arm, adjusting for clinical prognostic factors. Results: Two OS associations were statistically significant for each variant allele when compared with the wild-type: CTLA4: A49G [rs231775; adjusted HR (aHR), 1.32 (1.1–1.6); P = 0.01] and XRCC1: Arg339Gln [rs25487; aHR, 1.28 (1.05–1.57); P = 0.02]. Both of these sequence variants had significant results in the opposite direction as prior published literature. Two DFS associations were of borderline significance in the same direction as prior literature: ERCC2: Lys751Gln [rs13181; aHR, 0.80 (0.6–1.0); P = 0.05] and TP53: Arg72Pro [rs1042522; aHR, 1.28 (1.0–1.6); P = 0.03], comparing number of variant alleles with reference of zero variants. Conclusions: None of the prognostic sequence variants previously published was validated for OS in our patients with early-stage radiation-treated head and neck cancer, though rs1381and rs1042522 had borderline significant association with DFS. Clin Cancer Res; 18(1); 196–206. ©2011 AACR.

[1]  A. Azad,et al.  Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers , 2012, Cancer.

[2]  A. Scherag,et al.  Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas , 2011, Journal of Translational Medicine.

[3]  D. Cescon,et al.  Pharmacogenetic and Germline Prognostic Markers of Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  D. Christiani,et al.  Germline genetic variation, cancer outcome, and pharmacogenetics. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[6]  Chronic Disease Division.  Cancer facts and figures , 2010 .

[7]  A. Ghaderi,et al.  CTLA4 gene variations and haplotypes in patients with lung cancer. , 2010, Cancer genetics and cytogenetics.

[8]  D. Schadendorf,et al.  Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? , 2009, Cancer Immunology, Immunotherapy.

[9]  A. Fortin,et al.  Health-related quality of life as a survival predictor for patients with localized head and neck cancer treated with radiation therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Geoffrey Liu,et al.  Genetic variations in esophageal cancer risk and prognosis. , 2009, Gastroenterology clinics of North America.

[11]  Hongbing Shen,et al.  Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. , 2008, Cancer research.

[12]  D. Cescon,et al.  Genetic Polymorphisms and Head and Neck Cancer Outcomes: A Review , 2008, Cancer Epidemiology Biomarkers & Prevention.

[13]  Fan Wang,et al.  DNA Repair Gene XPD Polymorphisms and Cancer Risk: A Meta-analysis Based on 56 Case-Control Studies , 2008, Cancer Epidemiology Biomarkers & Prevention.

[14]  M. Pincus,et al.  Conformational Effects of a Common Codon 399 Polymorphism on the BRCT1 Domain of the XRCC1 Protein , 2007, The protein journal.

[15]  Shyun-Yeu Liu,et al.  Requirement of MMP-3 in anchorage-independent growth of oral squamous cell carcinomas. , 2007, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[16]  Wei Zhang,et al.  Polymorphic TP53BP1 and TP53 Gene Interactions Associated with Risk of Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.

[17]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[18]  J. Carles,et al.  Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. , 2006, International journal of radiation oncology, biology, physics.

[19]  A. Fortin,et al.  Antioxidant vitamins supplementation and mortality: A randomized trial in head and neck cancer patients , 2006, International journal of cancer.

[20]  M. Daly,et al.  Transferability of tag SNPs in genetic association studies in multiple populations , 2006, Nature Genetics.

[21]  R. Hitt,et al.  DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Hsiu‐Po Wang,et al.  Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Perez-Ordonez,et al.  Molecular biology of squamous cell carcinoma of the head and neck , 2006, Journal of Clinical Pathology.

[24]  R. Hayes,et al.  DNA Repair Gene Polymorphisms and Risk of Second Primary Neoplasms and Mortality in Oral Cancer Patients , 2005, The Laryngoscope.

[25]  Tomas Lindahl,et al.  Human DNA repair genes, 2005. , 2005, Mutation research.

[26]  J. Roy,et al.  Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Roy,et al.  A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. , 2005, Journal of the National Cancer Institute.

[28]  D. Tregouet,et al.  Matrix Metalloproteinase 3 Polymorphism , 2004, Clinical Cancer Research.

[29]  G. Hortobagyi,et al.  Prognostic molecular markers in early breast cancer , 2004, Breast Cancer Research.

[30]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[31]  C. Polychronakos,et al.  A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele* , 2002, The Journal of Biological Chemistry.

[32]  J. Luo,et al.  Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. , 2002, Mutation research.

[33]  P. Rieckmann,et al.  A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation , 2002, Immunogenetics.

[34]  H. Mohrenweiser,et al.  Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. , 2001, Carcinogenesis.

[35]  J. Hillert,et al.  CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms , 2001, Genes and Immunity.

[36]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[37]  C I Amos,et al.  Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. , 2001, Cancer research.

[38]  M. Fisfalen,et al.  CTLA-4 Gene Polymorphism at Position 49 in Exon 1 Reduces the Inhibitory Function of CTLA-4 and Contributes to the Pathogenesis of Graves’ Disease1 , 2000, The Journal of Immunology.

[39]  S. Z. Abdel‐Rahman,et al.  The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. , 2000, Cancer letters.

[40]  Z. Werb,et al.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter , 2000, Oncogene.

[41]  M. Spitz,et al.  Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. , 1999, Carcinogenesis.

[42]  D. Bell,et al.  XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. , 1999, Cancer research.

[43]  J. T. Reardon,et al.  The Non-catalytic Function of XPG Protein during Dual Incision in Human Nucleotide Excision Repair* , 1997, The Journal of Biological Chemistry.

[44]  A. Henney,et al.  Progression of Coronary Atherosclerosis Is Associated with a Common Genetic Variant of the Human Stromelysin-1 Promoter Which Results in Reduced Gene Expression* , 1996, The Journal of Biological Chemistry.

[45]  P. Sung,et al.  Human xeroderma pigmentosum group D gene encodes a DMA helicase , 1993, Nature.

[46]  P. Rubin.  Cancer of the head and neck. , 1972, JAMA.

[47]  E. Frazell,et al.  Cancer of the Head and Neck. , 1968 .

[48]  K. Chang,et al.  Association of CTLA-4 gene polymorphism with oral squamous cell carcinoma. , 2006, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[49]  Robert N. Hughes,et al.  Cancer: Principles and Practice of Oncology , 2005 .

[50]  R. Roberts,et al.  Insulin-like growth factor I, insulin-like growth factor binding protein 3, and urologic measures of benign prostatic hyperplasia. , 2003, American journal of epidemiology.

[51]  C. Weinberg,et al.  Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. , 2002, American journal of epidemiology.

[52]  S. Taylor.  Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.

[53]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .